Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

NCT05154994 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT05154994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05154994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2022
Completion date
April 28, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating urothelial carcinoma, sarcomatoid variant, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, unresectable urothelial carcinoma